Company: IMRX
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0001790340-25-000104
Chunk: 323

Company: Immuneering Corp
Filing Date: 2025-08-13
Form: 10-Q
Item: Part I, Item 1
Chunk 323
---
,313 — — 247,465 Stock-based compensation expense—— —— 1,474,758 — — 1,474,758 Net loss—— —— — — (14,307,829)(14,307,829)Other comprehensive income—— —— — (306)— (306)Balance at March 31, 202429,653,355$29,653 —$— $256,260,567 $(1,084)$(177,566,407)$78,722,729 Stock-based compensation expense—— —— 1,661,749 — — 1,661,749 Net loss—— —— — — (14,079,927)(14,079,927)Other comprehensive loss—— —— — 1,084 — 1,084 Balance at June 30, 202429,653,355$29,653 —$— $257,922,316 $— $(191,646,334)$66,305,635 

The accompanying notes are an integral part of these interim condensed consolidated financial statements.

10

IMMUNEERING CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE SIX MONTHS ENDED JUNE 30, 2025 and 2024

(Unaudited)

Six Months Ended June 30,20252024Cash flows from operating activities:Net loss$(29,480,012)$(28,387,756)Adjustment to reconcile to net loss to net cash used in operating activities:  Depreciation and amortization expense169,788 180,742 Reduction in carrying amount of right-of-use assets168,386 167,787 Intangible asset amortization14,633 14,633 Stock-based compensation expense3,217,210 3,136,507 Net accretion of discount on marketable securities— (169,351)Change in assets and liabilities:  (Increase) decrease in:  Prepaid expenses and other current assets2,072,921 (539,236)Other assets454,058 (193,644)Increase (decrease) in:  Accounts payable500,679 510,570 Accrued expenses(458,170)(1,416,812)Lease liabilities(162,298)(150,